Researchers
Andrić, Zoran
Results 21-40 of 89
| Issue Date | Title | Author(s) | Type | Мp-cat. |
|---|---|---|---|---|
| 2023 | Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study | Leal, Ticiana A; ...; Andric, Zoran G   ; ...; (broj, koautora 25) | Article | 21a+M21a+ |
| 2023 | Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results | Liu, SV; ...; Andric, Zoran G ; ...; (broj, koautora 24) | Conference Paper | Mp. category will be shown later |
| 2023 | Impact of TTFields therapy on global and functional health-related quality of life (HRQoL) in metastatic non-small cell lung cancer (mNSCLC) from the pivotal LUNAR study | Kotecha, R; ...; Andric, Zoran G ; ...; (broj, koautora 20) | Conference Paper | Mp. category will be shown later |
| 2023 | TTFields and Immune-Checkpoint Inhibitor in Metastatic Non-Small Cell Lung Cancer: PD-L1 Subgroups in the Phase 3 LUNAR Study | Leal, Ticiana A; ...; Andric, Zoran G ; ...; (broj, koautora 25) | Conference Paper | Mp. category will be shown later |
| 2022 | Randomized phase III study comparing the efficacy and safety of CT-P16, a new biosimilar, to reference bevacizumab (Avastin (R)) in patients with metastatic or recurrent non-small cell lung cancer (NSCLC) | Ohe, Yuichiro; ...; Andric, Zoran G ; ...; (broj, koautora 17) | Conference Paper | Mp. category will be shown later |
| 2022 | 1-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer | Verschraegen, Claire; Andric, Zoran G ; ...; (broj, koautora 20) | Conference Paper | Mp. category will be shown later |
| 2022 | HERIZON overall survival results: A study of IMU-131, a HER2 targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2 overexpressing metastatic or advanced gastric/GEJ cancer | Maglakelidze, Marina; Ryspayeva, D; Andric, Zoran G ; Petrovic, Zeljko M; Bulat, IV; Nikolic, Ivan V ; Chawla, T; Nagarkar, R; Wiedermann, Ursula; Blumenstein, BA;
Chong, LMO; Ede, NJ; Nixon, B; Good, AJ;
| Conference Paper | Mp. category will be shown later |
| 2022 | Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+NSCLC: Primary Analysis from JAVELIN Lung 100 | Reck, M; ...; Andric, Zoran G ; ...; (broj, koautora 19) | Conference Paper | Mp. category will be shown later |
| 2022 | Clinical potential of circulating tumor DNA (ctDNA)-based molecular response (MR) and baseline blood-based tumor mutational burden (bTMB) for monitoring response to firstline (1L) chemoimmunotherapy in advanced squamous non-small cell lung cancer (sqNSCLC | Ciardiello, F; Feng, Z; Smith, NR; Andric, Zoran G ; Shell, S; Yablonovitch, A; Guezel, G; Scheuenpflug, J | Conference Paper | Mp. category will be shown later |
| 2022 | Perioperative bevacizumab in the treatment of colorectal cancer in patients with liver metastases | Nikolić, Ivan ; Manojlović, Nebojša ; Andrić, Zoran ; Radosavljević, Davorin ; Ristić, Marija; Kovčin, Vladimir | Article | 51M51 |
| 2022 | Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2 | Goel, Shom; Tan, Antoinette R; Rugo, Hope S; Aftimos, Philippe; Andric, Zoran G ; Beelen, Andrew Paul; Zhang, Jingshan; Yi, John S; Malik, Rajesh K; O'Shaughnessy, Joyce | Article | 22M22 |
| 2022 | Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial | Verschraegen, Claire; Andric, Zoran G ; Moiseenko, Fedor; Makharadze, Tamta; Shevnya, Sergii; Oleksiienko, Alona; Ruiz, Eduardo Yanez; Kim, SungHyun; Ahn, KeumYoung; Park, TaeHong;
Park, Sijin; Ju, Hana; Ohe, Yuichiro;
| Article | 21aM21a |
| 2022 | Overweight and obesity in polycystic ovary syndrome: Association with inflammation, oxidative stress and dyslipidaemia | Perović-Blagojević, Iva; Vekić, Jelena ; Macut, Đuro ; Ignjatović, Svetlana ; Miljković-Trailović, Milica ; Zeljković, Aleksandra ; Spasojević-Kalimanovska, Vesna ; Božić-Antić, Ivana ; Bjekić-Macut, Jelica ; Kastratović-Kotlica, Biljana ;
Andrić, Zoran
; Ilić, Dušan; Kotur-Stevuljević, Jelena ; | Article | 22M22 |
| 2022 | Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial | Peters, Solange; ...; Andric, Zoran G ; ...; (broj, koautora 26) | Article | 21a+M21a+ |
| 2021 | A phase Ib/II study of the dual MDMX/MDM2 inhibitor, ALRN-6924, for the prevention of chemotherapy-induced myelosuppression | Andric, Zoran G ; Ceric, Timur; Rancic, Milan H ; Jakopovic, Marko; Aix, S Ponce; Ramlau, Rodryg; Ulanska, M; Caldwell, C; Ferrari, D; Annis, A;
Vukovic, V; Zaric, Bojan
; | Conference Paper | Mp. category will be shown later |
| 2021 | Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC) | Syrigos, Konstantinos; Abert, Istvan; Andric, Zoran G ; Bondarenko, Igor N; Dvorkin, Mikhail; Galic, Kristina; Galiulin, Rinat; Kuchava, Vladimer; Sriuranpong, Virote; Trukhin, Dmytro;
Zhavrid, Edvard; Fu, Dongyue; Kassalow, Laurent M; Jones, Stephanie; Bashir, Zahid;
| Article | 21aM21a |
| 2021 | Polycystic Ovary Syndrome: A Contemporary Clinical Approach | Bjekić-Macut, Jelica ; Vukašin, Tamara; Velija-Ašimi, Zelija; Bureković, Azra; Zdravković, Marija ; Andrić, Zoran ; Branković, Marija ; Crevar-Marinović, Slobodanka; Mandić, Tatjana; Stanojlović, Olivera ;
Vojnović-Milutinović, Danijela
; Livadas, Sarantis; Mastorakos, George; | Article | 22M22 |
| 2021 | HERIZON: Phase 2 part of the IMU-131 HER2/neu vaccine plus chemotherapy study randomized in patients with HER2/NEU overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction | Maglakelidze, Marina; ...; Andric, Zoran G ; Nikolic, Ivan V ; ...; Radosavljevic, Davorin Z ; Petrovic, Zeljko M; ...; (broj, koautora 16) | Conference Paper | Mp. category will be shown later |
| 2021 | A Phase 1b/2 Open-Label Study with Randomization in Phase 2 of Imu-131 Her2/Neu Peptide Vaccine Plus Standard of Care Chemotherapy in Patients with Her2/Neu Overexpressing Metastatic Or Advanced Adenocarcinoma of the Stomach Or Gastroesophageal Junction. | Maglakelidze, Marina; ...; Andric, Zoran G ; Nikolic, Ivan V ; ...; Radosavljevic, Davorin Z ; Petrovic, Zoran; ...; (broj, koautora 17) | Conference Paper | Mp. category will be shown later |
| 2021 | First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC) | Andric, Zoran G ; ...; Stojanovic, Goran; Petrovic, Marina D ; ...; (broj, koautora 20) | Conference Paper | Mp. category will be shown later |